FDA panel to review Moderna's mRNA flu vaccine for seniors

U.S. health advisers are meeting on Thursday to consider a first-of-its-kind influenza vaccine that utilizes mRNA technology. The Food and Drug Administration (FDA) advisory committee will review the proposal from Moderna for its new shot, which the company has named mFlusvia.

The vaccine is intended for individuals aged 50 and older. According to The Guardian, the committee's review is a key step toward a final regulatory decision, with the goal of making the shot available before the start of the winter flu season.

The technology underpinning mFlusvia is the same mRNA platform that was central to the development of vaccines used during the Covid-19 pandemic. The Independent reports that the new vaccine is facing scrutiny as advisers evaluate its potential as a tool for seasonal influenza.

The reports indicate that the regulatory process will assess whether the mRNA approach provides a viable alternative to current flu vaccines. While the specific results of the clinical trials were not detailed in the initial coverage, the meeting serves as the primary venue for health experts to debate the vaccine's readiness for the public.

The move into mRNA technology for influenza represents a broader application of the platform that gained global prominence in recent years. If the FDA grants approval, mFlusvia will join the existing landscape of flu prevention options for older populations.